Chaocai Zhang

Chaocai Zhang

Auto-generated profile, based on publicly available information

Chaocai Zhang

Department of Neurosurgery, Hainan General Hospital/Hainan Affiliated Hospital of Hainan Medical University, Haikou, China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 January 2021 in BioMed Research International
Verified
Journal Article
Open access
PDF file
CZChaocai Zhang
Chaocai Zhang
MWMinjie Wang
Minjie Wang
FJFenghu Ji
Fenghu Ji
YPYizhong Peng
Yizhong Peng
BWBo Wang
Bo Wang
HZHongyang Zhao
Hongyang Zhao
Introduction. Glioblastoma (GBM) is one of the most frequent primary intracranial malignancies, with limited treatment options and poor overall survival rates. Alternated glucose metabolism is a key metabolic feature of tumour cells, including GBM cells. However, due to high cellular heterogeneity, accurately predicting the prognosis of GBM patients using a single biomarker is difficult. Therefore, identifying a novel glucose metabolism‐related biomarker signature is important and may contribute to accurate prognosis prediction for GBM patients. Methods. In this research, we performed gene set enrichment analysis and profiled four glucose metabolism‐related gene sets containing 327 genes related to biological processes. Univariate and multivariate Cox regression analyses were specifically completed to identify genes to build a specific risk signature, and we identified ten mRNAs (B4GALT7, CHST12, G6PC2, GALE, IL13RA1, LDHB, SPAG4, STC1, TGFBI, and TPBG) within the Cox proportional hazards regression model for GBM. Results. Depending on this glucose metabolism‐related gene signature, we divided patients into high‐risk (with poor outcomes) and low‐risk (with satisfactory outcomes) subgroups. The results of the multivariate Cox regression analysis demonstrated that the prognostic potential of this ten‐gene signature is independent of clinical variables. Furthermore, we used two other GBM databases (Chinese Glioma Genome Atlas (CGGA) and REMBRANDT) to validate this model. In the functional analysis results, the risk signature was associated with almost every step of cancer progression, such as adhesion, proliferation, angiogenesis, drug resistance, and even an immune‐suppressed microenvironment. Moreover, we found that IL31RA expression was significantly different between the high‐risk and low‐risk subgroups. Conclusion. The 10 glucose metabolism‐related gene risk signatures could serve as an independent prognostic factor for GBM patients and might be valuable for the clinical management of GBM patients. The differential gene IL31RA may be a potential treatment target in GBM.

8 July 2022 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
MWMinjie Wang
Minjie Wang
ZZZijie Zhou
Zijie Zhou
XWXuan Wang
Xuan Wang
CZChaocai Zhang
Chaocai Zhang
XJXiaobing Jiang
Xiaobing Jiang
Due to the negligence of the complex tumor immune microenvironment, traditional treatment for glioblastoma has reached its limitation and cannot achieve a satisfying outcome in the past decade. The emergence of immunotherapy based on the theory of cancer-immunity cycle has brought a new dawn to glioblastoma patients. However, the results of most phase II and phase III clinical trials are not optimistic due to the simple focus on T cells activation rather than other immune cells involved in anti-tumor immunity. NK cells play a critical role in both innate and adaptive immunity, having the ability to coordinate immune response in inflammation, autoimmune disease and cancer. They are expected to cooperate with T cells to maximize the anti-tumor immune effect and have great potential in treating glioblastoma. Here, we describe the traditional treatment methods and current immunotherapy strategies for glioblastoma. Then, we list a microenvironment map and discuss the reasons for glioblastoma inhibitory immunity from multiple perspectives. More importantly, we focus on the advantages of NK cells as potential immune regulatory cells and the ways to maximize their anti-tumor immune effect. Finally, our outlook on the directions and potential applications of NK cell-based therapy combining with the advance technologies is presented. This review depicts NK cell awakening as the precondition to unleash the cancer-immunity cycle against glioblastoma and elaborate this idea from biology to clinical treatment.

13 March 2026 in Science Advances
Verified
Journal Article
Open access
MWMinjie Wang
Minjie Wang
SYShaojie Yu
Shaojie Yu
CZChaocai Zhang
Chaocai Zhang
QCQihong Cheng
Qihong Cheng
ZGZihan Gong
Zihan Gong
JLJun jun Li
Jun jun Li
Antigen loss is a major mechanism of resistance to immunotherapy. MIC-A/B are stress-inducible ligands expressed by tumor cells that activate NKG2D on cytotoxic immune cells and mediate NKG2D-dependent tumor cell killing, yet the mechanisms underlying their reduced expression in glioma remain unclear. Using single-cell RNA sequencing and spatial transcriptomics, we investigated ectopic MIC-A/B in mouse glioma and identified USP14 as a key regulator through deubiquitinase screening. Proteomic, coimmunoprecipitation, chromatin immunoprecipitation, immunofluorescence, and ubiquitination assays characterized the interactions among USP14, PARP1, and nuclear factor, interleukin 3 regulated (NFIL3), while an intracranial tumor model combined USP14 inhibition and immunotherapy to evaluate effects on tumorigenesis and antitumor immunity. We found that MIC-A/B increased CD8 + T cell infiltration and reversed exhaustion and that USP14 stabilized PARP1 via K63-linked deubiquitination at lysine-653, reducing NFIL3 binding to the MIC-A/B promoter through poly(ADP-ribosyl)ation. Inhibition of USP14 activated CD8 + T cells in a MIC-A/B–NKG2D–dependent, antigen-independent manner and synergized with PD1 blockade to prolong survival and enhance antitumor immunity. Clinical glioma specimens showed that the USP14 overexpression was correlated with PARP1 and dysfunctional CD8 + T cell infiltration. These results demonstrate that USP14 inhibition restores MIC-A/B–mediated CD8 + T cell activation, reverses immune exhaustion, and represents a promising strategy to enhance glioma immunotherapy.

20 January 2019 in FEBS Open Bio
Verified
Journal Article
Open access
PDF file
JCJianlong Chen
Jianlong Chen
PWPengcheng Wang
Pengcheng Wang
RCRenduan Cai
Renduan Cai
HPHao Peng
Hao Peng
CZChaocai Zhang
Chaocai Zhang
MZMao Zhang
Mao Zhang
Cancer stem cells (CSCs) contribute to cancer progression, but the mechanisms underlying neuroblastoma stem cell development are unclear. Here, we examined the roles of the transcription factor SLC34A2 in regulating the stemness of neuroblastoma cells. We found that SLC34A2 expression was negatively correlated with the overall survival and relapse‐free survival probability of neuroblastoma patients. Additionally, SLC34A2 expression was observed to be remarkably increased in spheroids derived from neuroblastoma cells. Knockdown of SLC34A2 attenuated the expression of stemness markers and spheroid formation capacity of neuroblastoma cell‐derived spheroids, and overexpression of SLC34A2 exerted the opposite effects in neuroblastoma cells. Mechanistically, SLC34A2 was found to directly bind to the promoter of MIR25, which targets Gsk3β (Glycogen synthesis kinase 3 β), an antagonist of Wnt signaling. Transfection of miR‐25 inhibitor or a Gsk3β overexpression plasmid attenuated the effects of SLC34A2 overexpression on the stemness of neuroblastoma cells. Our results demonstrate that miR‐25/Gsk3β‐mediated activation of Wnt signaling is responsible for SLC34A2‐induced enhancement of neuroblastoma cell stemness.

13 May 2021 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
MWMinjie Wang
Minjie Wang
ZZZijie Zhou
Zijie Zhou
JZJianglin Zheng
Jianglin Zheng
WXWenxuan Xiao
Wenxuan Xiao
JZJiameng Zhu
Jiameng Zhu
XJXiaobing Jiang
Xiaobing Jiang
Background: Glioma is the most common malignant brain tumor in adults, with its tumor-promoting immune microenvironment always being intricate to handle with. Amounts of evidence has accumulated to suggest that alternative splicing (AS) is related to tumor immune microenvironment. However, comprehensive analysis of immune-related AS events and their clinical significance are still lacking in glioma. Methods: AS events and transcriptome data of 653 glioma patients were downloaded online. ssGSEA was performed on transcriptome data of 653 patients to divided them into low, medium and high immune cell infiltration groups. Immune-related AS events were filtrated based on this grouping. Then lasso Cox regression analysis and multivariate Cox regression analysis were done to achieve an immune-related AS events prognostic signature for glioma. Kaplan-Meier analysis, ROC analyses, univariate Cox regression and multivariate Cox regression were performed to reveal the independent prognostic role of this signature. Meanwhile, a nomogram was constructed to achieved better prognostic value for glioma patients. Besides, functional enrichment analyses and correlation analyses with immune cells infiltration were used to validated the immune-related characteristic of this signature. Results: 36 immune-related AS events were achieved based on the grouping mentioned above. A nine-immune-related alternative splicing event signature was built for glioma patients. This signature showed an independent prognostic value and a nomogram containing gender, age, Karnofsky performance score, grade, IDH status, MGMT promoter status and risk score derived from the signature was constructed with a higher predictive ability for overall survival. Association with the infiltration of immune cell subtypes was validated and functional enrichment analysis found that the signature was mainly enriched in immune-related and pro-tumor functions. Conclusion: Our research presented all immune-related AS events in glioma, identified an immune-related prognostic AS events risk model and a nomogram was constructed to predict the prognosis individually and more precisely. Tight connection was verified between this signature and clinical characteristics. Also, immune cells infiltration and immune checkpoints expression level were proved to link to risk scores, which enhanced the understanding of relationship between AS events and glioma immune microenvironment, firstly revealing the potential role of AS in immunotherapy of glioma.

1 February 2021 in Clinical Neurology and Neurosurgery
Verified
Journal Article
Closed access
YWYibiao Wang
Yibiao Wang
RCRenduan Cai
Renduan Cai
PWPengcheng Wang
Pengcheng Wang
CHChuixue Huang
Chuixue Huang
CZChaocai Zhang
Chaocai Zhang
ZLZhaohui Liu
Zhaohui Liu